Mitochondrial dysfunction represents a critical pathological mechanism in progressive supranuclear palsy (PSP), a rare but devastating neurodegenerative disorder characterized by [tau](/proteins/tau-protein) protein aggregation, progressive [Parkinson's disease](/diseases/parkinsons-disease), and early postural instability with falls[@steele1964][@litvan1996]. Unlike idiopathic [Parkinson's disease](/diseases/parkinsons-disease), PSP demonstrates relatively limited response to dopaminergic therapies, suggesting that dysfunction in cellular energy metabolism and mitochondrial integrity may play a particularly prominent role in its pathogenesis[@burn2003]. The brain's high energy demands and reliance on mitochondrial function for neuronal survival make it particularly vulnerable to mitochondrial impairment, and evidence increasingly suggests that mitochondrial dysfunction in PSP extends beyond simple energy failure to encompass complex interactions between tau pathology, [oxidative stress](/mechanisms/oxidative-stress), and cellular bioenergetic compromise[@stamelou2023][@hglinger2024].
Mitochondrial dysfunction represents a critical pathological mechanism in progressive supranuclear palsy (PSP), a rare but devastating neurodegenerative disorder characterized by [tau](/proteins/tau-protein) protein aggregation, progressive [Parkinson's disease](/diseases/parkinsons-disease), and early postural instability with falls[@steele1964][@litvan1996]. Unlike idiopathic [Parkinson's disease](/diseases/parkinsons-disease), PSP demonstrates relatively limited response to dopaminergic therapies, suggesting that dysfunction in cellular energy metabolism and mitochondrial integrity may play a particularly prominent role in its pathogenesis[@burn2003]. The brain's high energy demands and reliance on mitochondrial function for neuronal survival make it particularly vulnerable to mitochondrial impairment, and evidence increasingly suggests that mitochondrial dysfunction in PSP extends beyond simple energy failure to encompass complex interactions between tau pathology, [oxidative stress](/mechanisms/oxidative-stress), and cellular bioenergetic compromise[@stamelou2023][@hglinger2024].
The relationship between mitochondrial dysfunction and PSP has become increasingly appreciated through neuroimaging studies, post-mortem brain analysis, and molecular investigations revealing deficits in complex I activity, altered mitochondrial dynamics, and impaired mitophagy[@schapira1999][@albers2000]. Furthermore, genetic studies have identified mutations in mitochondrial-related genes that may influence susceptibility to PSP, while animal models have demonstrated that mitochondrial toxins can produce tauopathic phenotypes with striking similarity to human PSP[@mart2003][@ferrer2023]. Understanding these mechanisms provides not only insight into PSP pathogenesis but also identifies potential therapeutic targets for disease-modifying interventions.
Neurons exhibit exceptionally high metabolic demands requiring continuous ATP production to maintain membrane potentials, support synaptic transmission, and drive intracellular transport[@attwell2001]. The central nervous system consumes approximately 20% of the body's total oxygen despite comprising only 2% of body weight, reflecting the enormous energy requirements of neural signaling and homeostasis[@raichle2002]. Mitochondria serve as the primary cellular power plants, generating ATP through oxidative phosphorylation via the electron transport chain (ETC), which consists of four complexes (I-IV) and ATP synthase (complex V)[@chance1956].
The unique vulnerability of neurons to mitochondrial dysfunction stems from several factors. First, neurons are post-mitotic cells that cannot dilute damaged components through cell division, making them particularly susceptible to the accumulation of defective mitochondria over time[@lane2020]. Second, neuronal axons and dendrites extend over long distances requiring coordinated mitochondrial distribution and local energy production at sites of high demand such as synapses[@sheng2014]. Third, the brain contains relatively limited antioxidant capacity compared to other organs, leaving neurons vulnerable to oxidative damage from mitochondrial reactive oxygen species (ROS) production[@halliwell1992].
In PSP, this baseline vulnerability is compounded by pathological processes that directly impair mitochondrial function. The accumulation of hyperphosphorylated [tau](/proteins/tau-protein) protein in neurons and glia disrupts cellular transport systems, potentially impairing mitochondrial trafficking to distal neuronal processes[@spiresjones2014]. Additionally, PSP is characterized by prominent neuronal loss in the [substantia nigra](/brain-regions/substantia-nigra), [globus pallidus](/brain-regions/globus-pallidus), subthalamic nucleus, and brainstem nuclei - regions with high baseline metabolic activity that may render them particularly susceptible to energy compromise[@dickson2010].
Mitochondrial function depends not only on proper ETC activity but also on dynamic processes of fission (division) and fusion (merging) that maintain a healthy mitochondrial population[@westermann2010]. These opposing processes, collectively termed mitochondrial dynamics, enable mitochondria to mix their contents, distribute functional mitochondria throughout neuronal processes, and remove damaged components through mitophagy[@youle2012].
The proteins regulating fission include Drp1 (dynamin-related protein 1), which is recruited from the cytosol to the mitochondrial outer membrane where it assembles around the organelle to catalyze division[@hoppins2007]. Fusion is mediated by mitofusins (MFN1, MFN2) for outer membrane fusion and OPA1 for inner membrane fusion[@chan2020]. Balanced fission-fusion dynamics ensure that functional mitochondria can replenish damaged regions through content mixing while enabling selective removal of severely compromised organelles[@twig2008].
Evidence suggests that mitochondrial dynamics are perturbed in PSP. Post-mortem studies have demonstrated altered expression of fission and fusion proteins in PSP brain tissue, with changes that would favor accumulation of dysfunctional mitochondria[@du2012]. Tau pathology itself may contribute to these alterations, as hyperphosphorylated [tau](/proteins/tau-protein) can interact with mitochondrial fission proteins and disrupt their normal function[@manczak2012]. Furthermore, [oxidative stress](/mechanisms/oxidative-stress) - a prominent feature of PSP pathogenesis - can modify mitochondrial dynamics proteins and shift the fission-fusion balance toward excessive fission, producing fragmented mitochondria with impaired function[@head2009].
Neuropathological investigations have provided direct evidence for mitochondrial impairment in PSP brain tissue. Biochemical studies of post-mortem brain samples from PSP patients have consistently demonstrated deficiencies in complex I activity of the electron transport chain[@schapira1990][@albers2001]. Complex I (NADH:ubiquinone oxidoreductase) represents the largest ETC complex and initiates electron transfer by oxidizing NADH, making its dysfunction particularly impactful for cellular energy production[@sazanov2015].
Importantly, complex I deficiency in PSP appears to be region-specific, corresponding to areas of greatest pathological involvement. The substantia nigra, which undergoes prominent neuronal loss in PSP, shows the most severe complex I deficits[@ferrer2014]. This regional specificity suggests that mitochondrial dysfunction in PSP is not simply a consequence of neurodegeneration but rather an active contributor to regional vulnerability[@gai1993].
Additional findings from post-mortem studies include evidence of mitochondrial DNA damage, with increased mutations and deletions detected in PSP brain tissue[@bender2006]. Mitochondrial DNA is particularly susceptible to oxidative damage due to its proximity to the ETC and lack of protective histones. Studies have also identified abnormalities in mitochondrial respiratory chain proteins, including reduced expression of several complex IV subunits in PSP brains[@keeney2006].
In vivo neuroimaging has provided additional evidence for mitochondrial dysfunction in PSP. Magnetic resonance spectroscopy (MRS) studies have demonstrated reduced N-acetylaspartate (NAA) levels in PSP brains, which serves as a marker of neuronal viability that can be affected by mitochondrial dysfunction[@federico1997][@tedeschi2004]. Additionally, phosphocreatine levels - an energy storage molecule that reflects mitochondrial ATP production capacity - are reduced in PSP patients, consistent with impaired cellular energetics[@rango2006].
Positron emission tomography (PET) studies using radiotracers for mitochondrial complex I have provided direct evidence of reduced complex I activity in living PSP patients[@barthel2002]. These findings correlate with clinical measures of disease severity, suggesting that the magnitude of mitochondrial impairment may contribute to functional deficits[@eckert2008]. Furthermore, FDG-PET studies have demonstrated characteristic patterns of hypometabolism in PSP that include brainstem and frontal regions, matching the distribution of tau pathology and supporting a role for energy compromise in disease expression[@garraux1997].
Genetic studies have further implicated mitochondrial dysfunction in PSP susceptibility and pathogenesis. While PSP is predominantly sporadic, rare pathogenic mutations in the MAPT gene (encoding tau) cause familial forms of the disorder, and genetic risk factors influence disease susceptibility[@hoglinger2011]. Notably, several mitochondrial-related genetic variants have been associated with PSP risk in genome-wide association studies (GWAS)[@chen2015].
The H1 haplotype of MAPT, which represents the major genetic risk factor for sporadic PSP, has been linked to altered mitochondrial function in cellular models[@testa2019]. Studies have demonstrated that neurons derived from H1-haplotype induced pluripotent stem cells (iPSCs) show increased sensitivity to mitochondrial stressors and altered bioenergetic profiles[@iovino2022]. Additionally, genes involved in mitochondrial quality control, including those regulating mitophagy, have been implicated in PSP risk[@liu2023].
Mitochondrial dysfunction in PSP is intimately connected to [oxidative stress](/mechanisms/oxidative-stress), with each process amplifying the other in a feedforward cycle[@andersen2004]. The electron transport chain inevitably produces reactive oxygen species (ROS), primarily superoxide anion (O₂⁻), as a byproduct of normal electron transfer[@turrens2003]. Under conditions of impaired electron flow - such as complex I deficiency - this ROS production is dramatically increased, creating a state of chronic oxidative stress[@murphy2009].
PSP brains show abundant evidence of oxidative damage, including elevated levels of lipid peroxidation products, protein oxidation markers, and DNA oxidation[@dexter1991][@floor1998]. The [substantia nigra](/brain-regions/substantia-nigra) appears particularly affected, consistent with the region's vulnerability to both oxidative stress and neuronal loss[@jenner1998]. Importantly, oxidative stress can directly damage mitochondrial components, including ETC proteins and mitochondrial DNA, further impairing function and creating additional ROS production[@lin2006].
The relationship between [tau](/proteins/tau-protein) pathology and oxidative stress deserves particular attention. Hyperphosphorylated tau can disrupt mitochondrial function through multiple mechanisms, including direct interaction with mitochondrial proteins and impairment of mitochondrial transport[@manczak2011]. Conversely, oxidative stress can promote tau phosphorylation through activation of kinases and inhibition of phosphatases, creating a pathogenic cycle linking protein aggregation and energy failure[@su2010].
Mitochondrial quality control is essential for maintaining cellular health, and impaired mitophagy - the selective autophagy of mitochondria - contributes to PSP pathogenesis[@youle2011]. Mitophagy recognizes damaged mitochondria through recognition of altered mitochondrial membrane potentials and ubiquitination of outer membrane proteins, targeting them for lysosomal degradation[@klionsky2000].
Multiple steps in the mitophagy pathway appear impaired in PSP. The PINK1-Parkin pathway, which senses mitochondrial damage and initiates mitophagy, shows dysfunction in PSP models[@van2011]. Additionally, the accumulation of damaged mitochondria in PSP brains suggests that even when mitophagy is initiated, completion of the process may be impaired[@park2020].
This failure of mitochondrial quality control has consequences beyond simple accumulation of dysfunctional organelles. Damaged mitochondria release pro-apoptotic factors such as cytochrome c, potentially triggering programmed cell death pathways[@green2005]. Furthermore, mitochondrial dysfunction activates inflammatory signaling through the NLRP3 inflammasome and other pattern recognition receptors, potentially contributing to the neuroinflammation observed in PSP[@zhou2011].
The relationship between [tau](/proteins/tau-protein) pathology and mitochondrial dysfunction represents a key mechanism linking protein aggregation to cellular energy failure in PSP[@sorrentino2017]. Tau protein normally associates with microtubules, where it stabilizes cytoskeletal structure and facilitates intracellular transport. In PSP, tau becomes hyperphosphorylated, aggregates into neurofibrillary tangles, and loses its normal cellular functions[@ballatore2007].
Importantly, tau can directly interact with mitochondria. Studies have demonstrated that hyperphosphorylated tau can localize to the mitochondrial outer membrane, where it may interfere with protein import and ETC function[@calkins2011]. Tau-mediated impairment of mitochondrial trafficking also contributes to dysfunction, as reduced mitochondrial delivery to synapses depletes local energy reserves at sites of high demand[@reddy2009].
The presence of mitochondria within tau aggregates in PSP brain tissue provides further evidence for these interactions[@yang2019]. This physical association may directly impair mitochondrial function while also sequestering functional mitochondria within non-functional aggregates. The specificity of PSP for 4R tau isoforms may relate to particular toxic properties of these variants, potentially including enhanced mitochondrial interaction[@bue1999].
Understanding mitochondrial dysfunction in PSP has identified several potential therapeutic targets. Coenzyme Q10 (CoQ10), an essential component of the ETC that shuttles electrons between complexes I/II and III, has shown promise in PSP clinical trials[@stamelou2008]. CoQ10 supplementation aims to bypass impaired electron transfer and restore efficient ATP production[@beal2002].
Additionally, mitochondrial antioxidants such as MitoQ (mitochondria-targeted coenzyme Q) have been investigated for their potential to reduce oxidative damage specifically within mitochondria[@smith2010]. These compounds accumulate within mitochondria due to their lipophilic cations, delivering antioxidants directly to the site of ROS production[@kelso2001].
Agents targeting mitochondrial dynamics represent another therapeutic approach. Inhibitors of excessive fission, such as Drp1 inhibitors, could potentially restore balanced mitochondrial dynamics and improve mitochondrial quality[@costa2010]. Similarly, compounds that enhance mitophagy, including [rapamycin](/therapeutics/rapamycin-tauopathy) and related agents, might improve clearance of damaged mitochondria[@rubinsztein2012].
Beyond directly targeting mitochondrial dysfunction, strategies to support cellular energy metabolism may benefit PSP patients. Metabolic cofactors including creatine and acetyl-L-carnitine have been investigated for their potential to enhance cellular energy reserves and support mitochondrial function[@bentoabreu2018][@jones2010]. These compounds may help neurons maintain function despite impaired ATP production.
Dietary interventions that promote ketogenesis have attracted interest for neurodegenerative diseases, including PSP. The ketogenic diet shifts cellular metabolism toward fatty acid oxidation and ketone body production, providing an alternative fuel source that may bypass defective complex I[@newman2014]. Preliminary studies suggest potential benefits, though systematic trials in PSP are needed[@phillips2018].
Animal models have provided important insights into the relationship between mitochondrial dysfunction and tauopathy. Administration of mitochondrial toxins, including 3-nitropropionic acid (3-NPA) and MPTP, produces parkinsonian phenotypes with varying degrees of tau pathology[@beal2001]. 3-NPA inhibits complex II of the ETC, producing selective striatal degeneration that recapitulates aspects of Huntington's disease, while also promoting tau phosphorylation[@brouillet2003].
MPTP, a complex I inhibitor that causes parkinsonism in humans and animal models, has been used to study the relationship between mitochondrial dysfunction and alpha-synuclein pathology. Interestingly, combined exposure to MPTP and other stressors can produce tauopathic changes, suggesting that mitochondrial dysfunction may serve as a common pathway for protein aggregation regardless of the specific misfolded protein[@thiruchelvam2005].
Transgenic models expressing human mutant tau demonstrate age-dependent tau pathology with accompanying mitochondrial dysfunction. These models show reduced complex I activity, impaired mitochondrial respiration, and altered mitochondrial dynamics that parallel findings in human PSP[@escott2023]. Notably, reducing mitochondrial dysfunction in these models through genetic or pharmacological interventions can reduce tau pathology, suggesting bidirectional relationships between protein aggregation and energy failure[@hu2023].
Mitochondrial dysfunction emerges as a central pathogenic mechanism in PSP, contributing to regional vulnerability, disease progression, and therapeutic resistance. The evidence encompasses post-mortem brain studies demonstrating complex I deficiency, neuroimaging studies showing impaired cerebral energy metabolism, genetic studies implicating mitochondrial-related genes in disease risk, and molecular investigations revealing oxidative stress, impaired mitophagy, and direct tau-mitochondria interactions. This mechanistic understanding identifies multiple potential therapeutic targets, including mitochondria-targeted antioxidants, ETC cofactors, modulators of mitochondrial dynamics, and enhancers of mitophagy. Future research should focus on validating these targets in clinical trials and developing biomarkers to monitor mitochondrial function in living patients, ultimately translating mechanistic insights into disease-modifying therapies for PSP.